PRINCETON, N.J., June 7, 2018 – Taiho Oncology, Inc. today announced that, in an effort to further support access for patients and their LONSURF® treatment, the co-pay for all dose strengths of LONSURF has been reduced from $30 to $0 per treatment cycle. The co-pay reduction, which took effect on May 1, 2018, is available to all patients with commercial prescription insurance coverage for LONSURF.
For patients without insurance, or for those who are significantly underinsured for LONSURF, the drug may be made available at no cost through Taiho Oncology’s Patient Assistance Program. The Taiho Oncology Patient Support service also provides information for patients and providers on LONSURF insurance coverage and specialty pharmacy availability.
Since the launch of LONSURF in October 2015, the Taiho Oncology Patient Support program has helped more than 10,000 patients afford their medication. More specifically, patients have utilized the Patient Assistance Program to receive more than 9,000 free prescriptions and the commercial Co-Pay Assistance Program on close to 6,000 prescriptions.
“For Taiho Oncology, patients and their well-being are at the center of everything we do as a company, so eliminating barriers to treatment is a high priority,” said Timothy Whitten, President and Chief Executive Officer of Taiho Oncology, Inc. “We understand that each patient has very specific support needs, and we are focused on providing – and regularly evaluating – our patient resources to see where we can further support access for patients. Our decision to eliminate the co-pay for LONSURF, for commercially insured patients, is another example of our commitment to easing the burden of people going through an incredibly challenging time in their lives.”